Neoadjuvant treatment for resectable pancreatic cancer: Time for phase III testing?
2010-01-01 Reni, M
Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
2017-01-01 Annemans, ; Aymé, ; Le, Cam; Facey, ; Gunther, ; Nicod, ; Reni, M; Roux, ; J., -L.; Schlander, ; Taylor, ; Tomino, ; Torrent-Farnell, ; Upadhyaya, ; Hutchings, ; Le, Dez
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
2016-01-01 Baumert, ; B., G.; Hegi, ; M., E.; van den, Bent; M., J.; Von, Deimling; Gorlia, ; Hoang-Xuan, ; Brandes, ; A., A.; Kantor, ; Taphoorn, ; M. J., B.; Hassel, ; M., B.; Hartmann, ; Ryan, ; Capper, ; Kros, ; J., M.; Kurscheid, ; Wick, ; Enting, ; Reni, M; Thiessen, ; Dhermain, ; Bromberg, ; J., E.; Feuvret, ; Reijneveld, ; J., C.; Chinot, ; Gijtenbeek, ; J. M., M.; Rossiter, ; J., P.; Dif, ; Balana, ; Bravo-Marques, ; Clement, ; P., M.; Marosi, ; Tzuk-Shina, ; Nordal, ; R., A.; Rees, ; Lacombe, ; Mason, ; W., P.; Stupp,
Extended abstract: Novel therapies against primary CNS lymphomas
2005-01-01 Ferreri, Ajm; Reni, M
Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial
2020-01-01 Golan, T; Kindler, Hl; Park, Jo; Reni, M; Macarulla, T; Hammel, P; Van Cutsem, E; Arnold, D; Hochhauser, D; Mcguinness, D; Locker, Gy; Goranova, T; Schatz, P; Liu, Yz; Hall, Mj.
Current management and prognostic factors for adult ependymoma.
2002-01-01 Reni, M; Brandes, A
Intra- and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning
1998-01-01 Fiorino, C; Reni, M; Bolognesi, A; Cattaneo, Gm; Calandrino, R
XELIRI or FOLFIRI as Salvage Therapy in Advanced Pancreatic Cancer
2010-01-01 Cereda, S; Reni, M; Rognone, A; Ghidini, M; Belli, C; Longoni, S; Fugazza, C; Brioschi, M; Nicoletti, R; Balzano, G; Passoni, P; Villa, E
Twofold unbranched coverings of genus two 3-manifolds are hyperelliptic
2001-01-01 Mednykh, A; Reni, M
Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas?
2004-01-01 Reni, M; Ferreri, Ajm
Unity is strength: one, two, or more drugs against advanced pancreatic cancer?
2011-01-01 Reni, M; Cereda, S; Belli, C; Villa, E
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients
2014-01-01 Maftouh, ; Avan, ; Funel, ; Paolicchi, ; Vasile, ; Pacetti, ; Vaccaro, ; Faviana, ; Campani, ; Caponi, ; Mambrini, ; Boggi, ; Cantore, ; Milella, ; Peters, ; G., J.; Reni, M; Giovannetti,
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies
2017-01-01 Chiaravalli, M; Reni, M; O'Reilly, Em
Whole-brain radiotherapy in primary CNS lymphoma
2011-01-01 Ferreri, Ajm; Deangelis, L; Illerhaus, G; O'Neill, Bp; Reni, M; Soussain, C; Yahalom, J
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy
2013-01-01 Mappa, ; Marturano, ; Licata, ; Frezzato, ; Frungillo, ; Ilariucci, ; Stelitano, ; Ferrari, ; Sorarù, ; Vianello, ; Baldini, ; Proserpio, ; Foppoli, ; Assanelli, ; Reni, M; Caligaris-Cappio, ; Ferreri, ; A. J., M.
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
2013-01-01 Von, Hoff; D., D.; Ervin, ; Arena, ; F., P.; Chiorean, ; E., G.; Infante, ; Moore, ; Seay, ; Tjulandin, ; S., A.; Ma, ; W., W.; Saleh, ; M., N.; Harris, ; Reni, M; Dowden, ; Laheru, ; Bahary, ; Ramanathan, ; R., K.; Tabernero, ; Hidalgo, ; Goldstein, ; Van, Cutsem; Wei, ; Iglesias, ; Renschler, ; M., F.
Weekly Epirubicin as Salvage Therapy in Patients with Gemcitabine-Resistant Advanced Pancreatic Cancer
2009-01-01 Cereda, S; Rognone, A; Mazza, E; Fugazza, C; Ceraulo, D; Villa, E; Reni, M
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: A dose-finding study
2007-01-01 Reni, M; Cereda, S; Bonetto, E; Vigano, Mg; Passoni, P; Zerbi, A; Balzano, G; Nicoletti, R; Staudacher, C; Di Carlo, V
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
2019-01-01 Hammel, P; Kindler, Hl; Reni, M; Van Cutsem, E; Macarulla, T; Hall, Mj; Park, Jo; Hochhauser, D; Arnold, D; Oh, Dy; Reinacher-Schick, A; Tortora, G; Algül, H; O'Reilly, Em; Mcguinness, D; Cui, Ky; Joo, S; Yoo, Hk; Patel, N; Golan, T
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma
2007-01-01 Reni, M; Cereda, S; Bonetto, E; Vigano, Mg; Passoni, P; Zerbi, A; Balzano, G; Nicoletti, R; Staudacher, C; Di Carlo, V
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Neoadjuvant treatment for resectable pancreatic cancer: Time for phase III testing? | 1-gen-2010 | Reni, M | |
| Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL) | 1-gen-2017 | Annemans, ; Aymé, ; Le, Cam; Facey, ; Gunther, ; Nicod, ; Reni, M; Roux, ; J., -L.; Schlander, ; Taylor, ; Tomino, ; Torrent-Farnell, ; Upadhyaya, ; Hutchings, ; Le, Dez | |
| Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study | 1-gen-2016 | Baumert, ; B., G.; Hegi, ; M., E.; van den, Bent; M., J.; Von, Deimling; Gorlia, ; Hoang-Xuan, ; Brandes, ; A., A.; Kantor, ; Taphoorn, ; M. J., B.; Hassel, ; M., B.; Hartmann, ; Ryan, ; Capper, ; Kros, ; J., M.; Kurscheid, ; Wick, ; Enting, ; Reni, M; Thiessen, ; Dhermain, ; Bromberg, ; J., E.; Feuvret, ; Reijneveld, ; J., C.; Chinot, ; Gijtenbeek, ; J. M., M.; Rossiter, ; J., P.; Dif, ; Balana, ; Bravo-Marques, ; Clement, ; P., M.; Marosi, ; Tzuk-Shina, ; Nordal, ; R., A.; Rees, ; Lacombe, ; Mason, ; W., P.; Stupp, | |
| Extended abstract: Novel therapies against primary CNS lymphomas | 1-gen-2005 | Ferreri, Ajm; Reni, M | |
| Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial | 1-gen-2020 | Golan, T; Kindler, Hl; Park, Jo; Reni, M; Macarulla, T; Hammel, P; Van Cutsem, E; Arnold, D; Hochhauser, D; Mcguinness, D; Locker, Gy; Goranova, T; Schatz, P; Liu, Yz; Hall, Mj. | |
| Current management and prognostic factors for adult ependymoma. | 1-gen-2002 | Reni, M; Brandes, A | |
| Intra- and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning | 1-gen-1998 | Fiorino, C; Reni, M; Bolognesi, A; Cattaneo, Gm; Calandrino, R | |
| XELIRI or FOLFIRI as Salvage Therapy in Advanced Pancreatic Cancer | 1-gen-2010 | Cereda, S; Reni, M; Rognone, A; Ghidini, M; Belli, C; Longoni, S; Fugazza, C; Brioschi, M; Nicoletti, R; Balzano, G; Passoni, P; Villa, E | |
| Twofold unbranched coverings of genus two 3-manifolds are hyperelliptic | 1-gen-2001 | Mednykh, A; Reni, M | |
| Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas? | 1-gen-2004 | Reni, M; Ferreri, Ajm | |
| Unity is strength: one, two, or more drugs against advanced pancreatic cancer? | 1-gen-2011 | Reni, M; Cereda, S; Belli, C; Villa, E | |
| A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients | 1-gen-2014 | Maftouh, ; Avan, ; Funel, ; Paolicchi, ; Vasile, ; Pacetti, ; Vaccaro, ; Faviana, ; Campani, ; Caponi, ; Mambrini, ; Boggi, ; Cantore, ; Milella, ; Peters, ; G., J.; Reni, M; Giovannetti, | |
| Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies | 1-gen-2017 | Chiaravalli, M; Reni, M; O'Reilly, Em | |
| Whole-brain radiotherapy in primary CNS lymphoma | 1-gen-2011 | Ferreri, Ajm; Deangelis, L; Illerhaus, G; O'Neill, Bp; Reni, M; Soussain, C; Yahalom, J | |
| Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy | 1-gen-2013 | Mappa, ; Marturano, ; Licata, ; Frezzato, ; Frungillo, ; Ilariucci, ; Stelitano, ; Ferrari, ; Sorarù, ; Vianello, ; Baldini, ; Proserpio, ; Foppoli, ; Assanelli, ; Reni, M; Caligaris-Cappio, ; Ferreri, ; A. J., M. | |
| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | 1-gen-2013 | Von, Hoff; D., D.; Ervin, ; Arena, ; F., P.; Chiorean, ; E., G.; Infante, ; Moore, ; Seay, ; Tjulandin, ; S., A.; Ma, ; W., W.; Saleh, ; M., N.; Harris, ; Reni, M; Dowden, ; Laheru, ; Bahary, ; Ramanathan, ; R., K.; Tabernero, ; Hidalgo, ; Goldstein, ; Van, Cutsem; Wei, ; Iglesias, ; Renschler, ; M., F. | |
| Weekly Epirubicin as Salvage Therapy in Patients with Gemcitabine-Resistant Advanced Pancreatic Cancer | 1-gen-2009 | Cereda, S; Rognone, A; Mazza, E; Fugazza, C; Ceraulo, D; Villa, E; Reni, M | |
| Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: A dose-finding study | 1-gen-2007 | Reni, M; Cereda, S; Bonetto, E; Vigano, Mg; Passoni, P; Zerbi, A; Balzano, G; Nicoletti, R; Staudacher, C; Di Carlo, V | |
| Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib | 1-gen-2019 | Hammel, P; Kindler, Hl; Reni, M; Van Cutsem, E; Macarulla, T; Hall, Mj; Park, Jo; Hochhauser, D; Arnold, D; Oh, Dy; Reinacher-Schick, A; Tortora, G; Algül, H; O'Reilly, Em; Mcguinness, D; Cui, Ky; Joo, S; Yoo, Hk; Patel, N; Golan, T | |
| Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma | 1-gen-2007 | Reni, M; Cereda, S; Bonetto, E; Vigano, Mg; Passoni, P; Zerbi, A; Balzano, G; Nicoletti, R; Staudacher, C; Di Carlo, V |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista39368
Data di pubblicazione
- In corso di stampa9
- 2020 - 202711455
- 2010 - 201915948
- 2000 - 20097460
- 1990 - 19993485
- 1980 - 1989933
- 1970 - 197977
- 1959 - 19591
Editore
- Elsevier Inc.802
- Elsevier B.V.767
- John Wiley and Sons Inc523
- Springer Science and Business Med...517
- Oxford University Press483
- Lippincott Williams and Wilkins420
- Springer359
- MDPI346
- Elsevier Ltd330
- Springer Nature280
Rivista
- EUROPEAN UROLOGY529
- BLOOD372
- PLOS ONE312
- JOURNAL OF NEUROLOGY283
- EUROPEAN JOURNAL OF HEART FAILURE280
- NEUROLOGY268
- DIGESTIVE AND LIVER DISEASE245
- EUROPEAN HEART JOURNAL224
- MULTIPLE SCLEROSIS216
- SCIENTIFIC REPORTS212
Keyword
- Humans3553
- Male2080
- Female1864
- Middle Aged1472
- Aged1290
- Adult1100
- COVID-19629
- Retrospective Studies628
- Treatment Outcome603
- Prognosis481
Lingua
- eng28777
- ita1956
- fre64
- und55
- spa34
- ger25
- por12
- enm6
- rus6
- grc3
Accesso al fulltext
- no fulltext33603
- open3370
- reserved2288
- partially open99
- embargoed7
- mixed1